About Blue Earth Capital

• Founded: 2014

• Headquarters: London, United Kingdom

• Strategy: Impact-focused secondaries, global

• Thesis: Acquires portfolios and direct stakes in mission-aligned funds and companies to provide liquidity while preserving impact objectives — positioning secondaries as an infrastructure play for the maturing impact market rather than purely opportunistic capital.

• Leadership: Lloyd Emelle (Founding Partner), Nick Silver (Partner)

Blue Earth Capital has reached a second close on its impact secondaries strategy at $200m in capital commitments. The close drew momentum primarily from the US, with Builders Vision, iAlumbra Capital, and Sonen Capital joining the investor base. The firm described the milestone as important progress for the strategy, though no final target or timeline was disclosed.

The raise signals sustained LP appetite for specialized secondaries strategies in a fundraising environment where generalist funds have struggled. Impact secondaries occupy a narrow niche — Blue Earth is one of fewer than five firms globally running dedicated impact secondaries vehicles — and the $200m close is notable given the strategy's limited track record compared to traditional secondaries franchises. Coller Capital and Lexington Partners, by comparison, have each raised multi-billion-dollar flagship funds in the past two years, but neither dedicates a carve-out to impact. The question is whether Blue Earth's LP base widens beyond family offices and impact-mandated allocators, or if the strategy remains subscale relative to peers.

What matters over the next 12–18 months is deployment pace and the quality of portfolio liquidity Blue Earth can source. Impact funds have historically seen lower secondary transaction volumes than venture or buyout — exit timelines are longer, and fewer GPs list on impact-focused continuation vehicles. If Blue Earth can demonstrate consistent deal flow and competitive entry multiples, the strategy's differentiation holds. If sourcing proves thin, the fund risks becoming a patient capital vehicle in a market structure that doesn't yet generate sufficient secondary supply.

Source: AltAssets